These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 30392809)

  • 1. Venetoclax with decitabine or azacitidine for AML.
    Das M
    Lancet Oncol; 2018 Dec; 19(12):e672. PubMed ID: 30392809
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypomethylating agents and venetoclax in acute myeloid leukemia.
    DiNardo CD
    Clin Adv Hematol Oncol; 2021 Feb; 19(2):82-83. PubMed ID: 33596188
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
    Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
    Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
    Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
    Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
    Pollyea DA; Pratz K; Letai A; Jonas BA; Wei AH; Pullarkat V; Konopleva M; Thirman MJ; Arellano M; Becker PS; Chyla B; Hong WJ; Jiang Q; Potluri J; DiNardo CD
    Am J Hematol; 2021 Feb; 96(2):208-217. PubMed ID: 33119898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.
    Otoukesh S; Salhotra A; Marcucci G; Forman SJ; Pullarkat V; Aldoss I
    Leuk Res; 2019 Sep; 84():106196. PubMed ID: 31377457
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy.
    Acker F; Chromik J; Tiedjen E; Wolf S; Vischedyk JB; Makowka P; Enßle JC; Kouidri K; Sebastian M; Steffen B; Oellerich T; Serve H; Neubauer A; Schäfer JA; Bittenbring JT
    Eur J Haematol; 2024 Nov; 113(5):623-630. PubMed ID: 39023132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
    DiNardo CD; Pratz K; Pullarkat V; Jonas BA; Arellano M; Becker PS; Frankfurt O; Konopleva M; Wei AH; Kantarjian HM; Xu T; Hong WJ; Chyla B; Potluri J; Pollyea DA; Letai A
    Blood; 2019 Jan; 133(1):7-17. PubMed ID: 30361262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schuler E; Wagner-Drouet EM; Ajib S; Bug G; Crysandt M; Dressler S; Hausmann A; Heidenreich D; Hirschbühl K; Hoepting M; Jost E; Kaivers J; Klein S; Koldehoff M; Kordelas L; Kriege O; Müller LP; Rautenberg C; Schaffrath J; Schmid C; Wolff D; Haas R; Bornhäuser M; Schroeder T; Kobbe G;
    Ann Hematol; 2021 Apr; 100(4):959-968. PubMed ID: 33191481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
    DiNardo CD; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Wei AH; Konopleva M; Döhner H; Letai A; Fenaux P; Koller E; Havelange V; Leber B; Esteve J; Wang J; Pejsa V; Hájek R; Porkka K; Illés Á; Lavie D; Lemoli RM; Yamamoto K; Yoon SS; Jang JH; Yeh SP; Turgut M; Hong WJ; Zhou Y; Potluri J; Pratz KW
    N Engl J Med; 2020 Aug; 383(7):617-629. PubMed ID: 32786187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings.
    Taniguchi S; Yamauchi T; Choi I; Fukuhara N; Potluri J; Salem AH; Hong WJ; Honda H; Nishimura Y; Okubo S; Usuki K
    Jpn J Clin Oncol; 2021 May; 51(6):857-864. PubMed ID: 33712849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
    Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
    Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates on DNA methylation modifiers in acute myeloid leukemia.
    Contieri B; Duarte BKL; Lazarini M
    Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
    Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.
    Andreani G; Dragani M; Serra A; Nicoli P; De Gobbi M; Cilloni D
    Am J Hematol; 2019 Feb; 94(2):E48-E50. PubMed ID: 30431666
    [No Abstract]   [Full Text] [Related]  

  • 18. A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.
    Murthy GSG; Saliba AN; Szabo A; Harrington A; Abedin S; Carlson K; Michaelis L; Runaas L; Baim A; Hinman A; Maldonado-Schmidt S; Venkatachalam A; Flatten KS; Peterson KL; Schneider PA; Litzow M; Kaufmann SH; Atallah E
    Haematologica; 2024 Sep; 109(9):2864-2872. PubMed ID: 38572562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis.
    He H; Wen X; Zheng H
    Hematology; 2024 Dec; 29(1):2343604. PubMed ID: 38703055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.
    Wu X; Zhang J; Chen Q; Zhou L; Li M; Qiu H; Sun A; Wu D
    Br J Haematol; 2020 Jun; 189(5):e200-e204. PubMed ID: 32242923
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 29.